Vitamin D and inflammatory bowel disease

Vitamin D

Volumn , Issue , 2011, Pages 1879-1889

  Bruce, Danny ^a   Cantorna, Margherita T ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84655173722     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381978-9.10096-4     Document Type: Chapter

References (109)

1. Podolsky D.K. Inflammatory bowel disease (1). N. Engl. J. Med. 1991, 325:928-937.
2. Podolsky D.K. Inflammatory bowel disease (2). N. Engl. J. Med. 1991, 325:1008-1016.
3. Braus N.A., Elliott D.E. Advances in the pathogenesis and treatment of IBD. Clin. Immunol. 2009, 132:1-9.
4. Bernstein C.N., Wajda A., Svenson L.W., MacKenzie A., Koehoorn M., Jackson M., et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 2006, 101:1559-1568.
5. Cantorna M.T. Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog. Biophys. Mol. Biol. 2006, 92:60-64.
6. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
7. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
8. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
9. Cooney R., Jewell D. The genetic basis of inflammatory bowel disease. Dig. Dis. 2009, 27:428-442.
10. Satsangi J., Jewell D.P., Bell J.I. The genetics of inflammatory bowel disease. Gut. 1997, 40:572-574.
11. Louis E., Libioulle C., Reenaers C., Belaiche J., Georges M. Genetics of ulcerative colitis: the come-back of interleukin 10. Gut. 2009, 58:1173-1176.
12. Jalocha L., Wojtun S., Dyrla P., Gil J., Korsak J., Rzeszotarska A., et al. [TNF alfa polymorphism and course of ulcerative colitis]. Pol. Merkur. Lekarski. 2009, 26:444-445.
13. Li K., Yao S., Liu S., Wang B., Mao D. Genetic polymorphisms of interleukin 8 and risk of ulcerative colitis in the Chinese population. Clin. Chim. Acta. 2009, 405:30-34.
14. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 2008, 8:458-466.
15. Luo Y., Xia B., Li C., Chen Z., Ge L., Jiang T., et al. Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients. Int. J. Colorectal. Dis. 2009, 24:489-493.
16. Verma R., Ahuja V., Paul J. Frequency of single nucleotide polymorphisms in NOD1 gene of ulcerative colitis patients: a case-control study in the Indian population. BMC Med. Genet. 2009, 10:82.
17. Shen X., Shi R., Zhang H., Li K., Zhao Y., Zhang R. The Toll-like receptor 4 D299G and T399I polymorphisms are associated with Crohn's disease and ulcerative colitis: a meta-analysis. Digestion 2010, 81:69-77.
18. Zaki M.H., Boyd K.L., Vogel P., Kastan M.B., Lamkanfi M., Kanneganti T.D. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010, 32:379-391.
19. McCullough M.L., Bostick R.M., Mayo T.L. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr. 2009, 29:111-132.
20. Simmons J.D., Mullighan C., Welsh K.I., Jewell D.P. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 2000, 47:211-214.
21. Dresner-Pollak R., Ackerman Z., Eliakim R., Karban A., Chowers Y., Fidder H.H. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet. Test 2004, 8:417-420.
22. van Etten E., Stoffels K., Gysemans C., Mathieu C., Overbergh L. Regulation of vitamin D homeostasis: implications for the immune system. Nutr. Rev. 2008, 66:S125-134.
23. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1?1501 is regulated by vitamin D. PLoS Genet. 2009, 5:e1000369.
24. Israni N., Goswami R., Kumar A., Rani R. Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India. PLoS One 2009, 4:e8023.
25. Wang T.T., Dabbas B., Laperriere D., Bitton A.J., Soualhine H., Tavera-Mendoza L.E., et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J. Biol. Chem. 2010, 285:2227-2231.
26. Orton S.M., Morris A.P., Herrera B.M., Ramagopalan S.V., Lincoln M.R., Chao M.J., et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am. J. Clin. Nutr. 2008, 88:441-447.
27. Anderson C.A., Massey D.C., Barrett J.C., Prescott N.J., Tremelling M., Fisher S.A., et al. Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 2009, 136:523-529. e523.
28. Koloski N.A., Bret L., Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J. Gastroenterol. 2008, 14:165-173.
29. van der Heide F., Dijkstra A., Weersma R.K., Albersnagel F.A., van der Logt E.M., Faber K.N., et al. Effects of active and passive smoking on disease course of Crohn's disease and ulcerative colitis. Inflamm. Bowel. Dis. 2009, 15:1199-1207.
30. Kitajima S., Morimoto M., Sagara E., Shimizu C., Ikeda Y. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. Exp. Anim. 2001, 50:387-395.
31. Hansen R., Thomson J.M., El-Omar E.M., Hold G.L. The role of infection in the aetiology of inflammatory bowel disease. J. Gastroenterol. 2010, 45:266-276.
32. Pierce E.S. Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease?. PLoS Pathog. 2009, 5:e1000234.
33. Bufford J.D., Gern J.E. The hygiene hypothesis revisited. Immunol. Allergy. Clin. North Am. 2005, 25:247-262. v-vi.
34. Koloski N.A., Brett L. Animal farm: do our four-legged friends hold the answer to inflammatory bowel disease?. Inflamm. Bowel. Dis. 2008, 14:1163-1164.
35. Cantorna M.T., Yu S., Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. Mol. Aspects. Med. 2008, 29:369-375.
36. Holick M.F. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need?. Adv. Exp. Med. Biol. 2008, 624:1-15.
37. DeLuca H.F. Vitamin D. Nutrition. Today 1993, 28:6-11.
38. Kampman M.T., Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology 2008, 30:140-146.
39. Mullin G.E., Turnbull L., Kines K. Vitamin D: a D-lightful health supplement. Nutr. Clin. Pract. 2009, 24:642-644.
40. Ybarra J., Sanchez-Hernandez J., Perez A. Hypovitaminosis D and morbid obesity. Nurs. Clin. North Am. 2007, 42:19-27. v.
41. Steed H., Walsh S., Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes. Facts 2009, 2:370-372.
42. Pappa H.M., Grand R.J., Gordon C.M. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm. Bowel. Dis. 2006, 12:1162-1174.
43. Katz S. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment. Rev. Gastroenterol. Disord. 2006, 6:63-71.
44. Rodriguez-Bores L., Barahona-Garrido J., Yamamoto-Furusho J.K. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J. Gastroenterol. 2007, 13:6156-6165.
45. Vestergaard P., Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am. J. Epidemiol. 2002, 156:1-10.
46. Lee S.H., Kim H.J., Yang S.K., Kim W.H., Joo Y.S., Dong S.H., et al. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J. Gastroenterol. Hepatol. 2000, 15:512-518.
47. Guarner F., Malagelada J.R. Gut flora in health and disease. Lancet 2003, 361:512-519.
48. Zenewicz L.A., Antov A., Flavell R.A. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol. Med. 2009, 15:199-207.
49. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 2007, 13:1173-1175.
50. Costa V.S., Mattana T.C., da Silva M.E. Unregulated IL-23/IL-17 immune response in autoimmune diseases. Diabetes Res. Clin. Pract. 2010, 88:222-226.
51. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 1996, 157:1261-1270.
52. Das K.M., Dasgupta A., Mandal A., Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J. Immunol. 1993, 150:2487-2493.
53. Saxon A., Shanahan F., Landers C., Ganz T., Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J. Allergy Clin. Immunol. 1990, 86:202-210.
54. Middendorp S., Nieuwenhuis E.E. NKT cells in mucosal immunity. Mucosal Immunol. 2009, 2:393-402.
55. Hammond K.J., Godfrey D.I. NKT cells: potential targets for autoimmune disease therapy?. Tissue Antigens 2002, 59:353-363.
56. Grose R.H., Thompson F.M., Baxter A.G., Pellicci D.G., Cummins A.G. Deficiency of invariant NK T cells in Crohn's disease and ulcerative colitis. Dig. Dis. Sci. 2007, 52:1415-1422.
57. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
58. Leishman A.J., Naidenko O.V., Attinger A., Koning F., Lena C.J., Xiong Y., et al. T cell responses modulated through interaction between CD8alphaalpha and the nonclassical MHC class I molecule. TL. Science 2001, 294:1936-1939.
59. Cheroutre H. Starting at the beginning: new perspectives on the biology of mucosal T cells. Annu. Rev. Immunol. 2004, 22:217-246.
60. Poussier P., Ning T., Banerjee D., Julius M. A unique subset of self-specific intraintestinal T cells maintains gut integrity. J. Exp. Med. 2002, 195:1491-1497.
61. Tang X., Maricic I., Kumar V. Anti-TCR antibody treatment activates a novel population of nonintestinal CD8 alpha alpha+ TCR alpha beta+ regulatory T cells and prevents experimental autoimmune encephalomyelitis. J. Immunol. 2007, 178:6043-6050.
62. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem. Biophys. 2000, 374:334-338.
63. Froicu M., Weaver V., Wynn T.A., McDowell M.A., Welsh J.E., Cantorna M.T. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 2003, 17:2386-2392.
64. Zhu Y., Mahon B.D., Froicu M., Cantorna M.T. Calcium and 1alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur. J. Immunol. 2005, 35:217-224.
65. Griffin M.D., Kumar R. Effects of 1alpha,25(OH)2D3 and its analogs on dendritic cell function. J. Cell Biochem. 2003, 88:323-326.
66. Penna G., Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 2000, 164:2405-2411.
67. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 2002, 51:2119-2125.
68. Koeffler H.P., Amatruda T., Ikekawa N., Kobayashi Y., DeLuca H.F. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 1984, 44:5624-5628.
69. Clohisy D.R., Bar-Shavit Z., Chappel J.C., Teitelbaum S.L. 1,25-Dihydroxyvitamin D3 modulates bone marrow macrophage precursor proliferation and differentiation. Up-regulation of the mannose receptor. J. Biol. Chem. 1987, 262:15922-15929.
70. Cippitelli M., Santoni A. Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur. J. Immunol. 1998, 28:3017-3030.
71. Reichel H., Koeffler H.P., Tobler A., Norman A.W. 1 Alpha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 1987, 84:3385-3389.
72. Ardizzone S., Cassinotti A., Trabattoni D., Manzionna G., Rainone V., Bevilacqua M., et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int. J. Immunopathol. Pharmacol. 2009, 22:63-71.
73. Daniel C., Sartory N.A., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 2008, 324:23-33.
74. Tang J., Zhou R., Luger D., Zhu W., Silver P.B., Grajewski R.S., et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol. 2009, 182:4624-4632.
75. Laverny G., Penna G., Vetrano S., Correale C., Nebuloni M., Danese S., et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol. Lett. 2010, 131:49-58.
76. Mahon B.D., Wittke A., Weaver V., Cantorna M.T. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J. Cell Biochem. 2003, 89:922-932.
77. Boonstra A., Barrat F.J., Crain C., Heath V.L., Savelkoul H.F., O'Garra A. 1Alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J. Immunol. 2001, 167:4974-4980.
78. Pichler J., Gerstmayr M., Szepfalusi Z., Urbanek R., Peterlik M., Willheim M. 1 Alpha,25(OH)2D3 inhibits not only Th1 but also Th2 differentiation in human cord blood T cells. Pediatr. Res. 2002, 52:12-18.
79. Yu S., Cantorna M.T. The vitamin D receptor is required for iNKT cell development. Proc. Natl. Acad. Sci. USA 2008, 105:5207-5212.
80. Froicu M., Cantorna M.T. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007, 8:5.
81. Driver J.P., Foreman O., Mathieu C., van Etten E., Serreze D.V. Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin. Exp. Immunol. 2008, 151:76-85.
82. Yu S., Bruce D., Froicu M., Weaver V., Cantorna M.T. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc. Natl. Acad. Sci. USA 2008, 105:20834-20839.
83. Adorini L., Penna G. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 2009, 70:345-352.
84. Froicu M., Zhu Y., Cantorna M.T. Vitamin D receptor is required to control gastrointestinal immunity in IL-10 knockout mice. Immunology 2006, 117:310-318.
85. Cantorna M.T., Munsick C., Bemiss C., Mahon B.D. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J. Nutr. 2000, 130:2648-2652.
86. Aranda R., Sydora B.C., McAllister P.L., Binder S.W., Yang H.Y., Targan S.R., et al. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RB high T cells to SCID recipients. J. Immunol. 1997, 158:3464-3473.
87. Powrie F., Leach M.W., Mauze S., Caddle L.B., Coffman R.L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 1993, 5:1461-1471.
88. Das G., Augustine M.M., Das J., Bottomly K., Ray P., Ray A. An important regulatory role for CD4+CD8 alpha alpha T cells in the intestinal epithelial layer in the prevention of inflammatory bowel disease. Proc. Natl. Acad. Sci. USA 2003, 100:5324-5329.
89. Kong J., Zhang Z., Musch M.W., Ning G., Sun J., Hart J., et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294:G208-216.
90. Bemiss C.J., Mahon B.D., Henry A., Weaver V., Cantorna M.T. Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system. Arch. Biochem. Biophys. 2002, 402:249-254.
91. Lichtenstein G.R., Kamm M.A. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment. Pharmacol. Ther. 2008, 28:663-673.
92. van Bodegraven A.A., Mulder C.J. Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?. World J. Gastroenterol. 2006, 12:6115-6123.
93. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
94. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
95. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
96. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Intern. Med. 1995, 123:132-142.
97. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Ludviksson B.R., Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin. Immunol. 2005, 114:154-163.
98. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 1995, 332:292-297.
99. Chande N., MacDonald J.K., McDonald J.W. Methotrexate for induction of remission in ulcerative colitis. Cochrane. Database Syst. Rev. 2007, CD006618.
100. Liu J.O. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunol. Rev. 2009, 228:184-198.
101. Burakoff R. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?. Inflamm. Bowel. Dis. 2008, 14(Suppl. 2):S202-203.
102. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane. Database Syst. Rev. 2008, CD006893.
103. Rutgeerts P., Van Assche G., Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004, 126:1593-1610.
104. Yamamoto-Furusho J.K. Innovative therapeutics for inflammatory bowel disease. World J. Gastroenterol. 2007, 13:1893-1896.
105. Yu Q.T., Saruta M., Papadakis K.A. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin. Immunol. 2008, 127:322-329.
106. Rosenstiel P., Sina C., Franke A., Schreiber S. Towards a molecular risk map - recent advances on the etiology of inflammatory bowel disease. Semin. Immunol. 2009, 21:334-345.
107. Kang S.S., Bloom S.M., Norian L.A., Geske M.J., Flavell R.A., Stappenbeck T.S., et al. An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med. 2008, 5:e41.
108. Looijer-van Langen M.A., Dieleman L.A. Prebiotics in chronic intestinal inflammation. Inflamm. Bowel. Dis. 2009, 15:454-462.
109. Miheller P., Muzes G., Hritz I., Lakatos G., Pregun I., Lakatos P.L., et al. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm. Bowel. Dis. 2009, 15:1656-1662.